Replies to post #146902 on Biotech Values

[jq1234]

Small biotechs are going to raise money, it is way of life for them. The question is always when and how much at what term. 110 is the one that is going to cost money, 011 is not costing much from now on because the trial is just follow up for survival at this point. Other trials are small. Hopefully they'll raise some around 011 data in Dec, or partnership at that point.

[bladerunner1717]

re; CLDX

BTH,

Here's my "reading" on the partnership. Mariucci has told us that there are ongoing partnership discussions. He has also told us that prospective partners do NOT need to see the data that is going to be presented at SABC in December. Furthermore, he has stated that CLDX hasn't met with the FDA on a design for the Phase III. Yet, he has told us that the Phase III will begin, no matter what, by the 3rd quarter of 2013. I put this all together and I get that there will be a partnership before SABC and that the partner will handle the design of the Phase III and all regulatory issues with the FDA. (Remember this post!!! LOLOL)


Bladerunner